Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 35,355 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Hereditary Angioedema
Interventions: KVD900, Placebo; Drug · Other
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Scottsdale, Arizona • Centennial, Colorado • Chevy Chase, Maryland + 3 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 44
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 27 more

Conditions: HIV, Acquired Immunodeficiency Syndrome, Immunologic Deficiency Syndrome, Acquired, Sexually Transmitted Diseases, Viral, Retroviridae Infections
Interventions: Ad26.Mos4.HIV, MVA-BN-HIV, PGT121, PGDM1400, VRC07-523LS; Biological
Lead sponsor: Boris Juelg, MD PhD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Orlando, Florida • Boston, Massachusetts + 3 more

Conditions: Allergic Conjunctivitis, Allergic Rhinitis
Interventions: Dose Level 1, Dose Level 2, Placebo; Biological
Lead sponsor: Woodmont Pharmaceuticals, Inc.; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: HIV Infections
Interventions: Alovudine; Drug
Lead sponsor: Lederle Laboratories; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: NSCLC, Stage I
Interventions: Pembrolizumab; Drug
Lead sponsor: Greg Durm, MD; Other
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 13
States / cities: Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 10 more

Conditions: Pain Catastrophizing, Pain, Chronic, Gender Identity
Interventions: Empowered Relief, Standard of Care; Behavioral · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anemia, Arthritis, Total Knee Arthroplasty, Total Hip Arthroplasty
Interventions: Conventional Oral TXA (Tranexamic Acid), Multi-Dose Oral TXA (Tranexamic Acid); Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Youth Health SMS; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 15 Years to 19 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Malignancy, Cancer, Oncology, Oncology Patients, Acute Myeloid Leukemia
Interventions: AMG 232, Trametinib; Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Birmingham, Alabama • Buffalo, New York • Charlotte, North Carolina + 2 more

Conditions: Healthy
Interventions: MT400; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Safety Issues
Interventions: Placebo, PH100 100mg, PH100 200mg, PH100 400mg, PH100 800mg, PH100 1200mg, PH100 1600mg; Drug
Lead sponsor: Phloronol Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
Interventions: Sofe-M, bevacizumab, carboplatin, Itraconazole, pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 11
States / cities: Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more

Conditions: Skin and Soft Tissue Infections, Methicillin-resistant Staphylococcus Aureus
Interventions: EDP-322; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Locally Advanced or Metastatic Solid Tumors
Interventions: ANS014004; Drug
Lead sponsor: Avistone Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Orlando, Florida + 5 more

Conditions: Chronic Myelogenous Leukemia in Chronic Phase
Interventions: Nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 32
States / cities: Anaheim, California • Burbank, California • Concord, California + 27 more

Conditions: Influenza, Healthy
Interventions: Fluzone®, FluMist®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 10 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Vitreomacular Adhesion
Interventions: Intravitreal Injection of sulfahexafluoride gas; Procedure
Lead sponsor: Northern California Retina Vitreous Associates; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Cerebral Palsy
Interventions: Infusion of allogeneic umbilical cord blood, Infusion of MSCs; Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 24 Months to 60 Months
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ovarian Cancer
Interventions: ABT-888, pegylated liposomal doxorubicin, temozolomide; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: Duarte, California • Encino, California • Los Angeles, California + 12 more

Conditions: HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Interventions: Denikitug, Nivolumab, Ramucirumab, Paclitaxel; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: Boston, Massachusetts • Albany, New York • New York, New York

Conditions: Breast Cancer, Early-stage Breast Cancer
Interventions: Fasting; Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Solid Tumors
Interventions: Iniparib (SAR240550/BSI-201), Carboplatin, Doxorubicin HCL liposome injection, Gemcitabine, Irinotecan, Paclitaxel, Topotecan; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • Santa Maria, California • Vallejo, California + 25 more

Conditions: COPD
Interventions: indacaterol, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 6
States / cities: Fullerton, California • Saint Charles, Missouri • Charlotte, North Carolina + 3 more

Search by objective public record fields.

A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections

An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Efficacy of a Chronic Pain Treatment Prior to Gender-affirming Surgery

Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty

Using Mobile Technology to Prevent HIV and Related Youth Health Problems

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets

Phase I Study of PH100 (Ecklonia Cava Phlorotannins)

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

Intravitreal Gas for Vitreomacular Adhesion

A Study of UCB and MSCs in Children With CP: ACCeNT-CP

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease